Sweden's Getinge Q2 organic sales rise on acute care therapies growth

Getinge publ AB

17/07/2026 07:11

Overview
Sweden medical technology firm's Q2 organic net sales grew 4.6% yr/yr
Adjusted EPS for Q2 rose to SEK 3.59 from SEK 2.25 yr/yr
Q2 adjusted EBITA margin improved, aided by tariff refund and operational gains

Outlook
Getinge maintains forecast of 3-5% organic sales growth in 2026
Company says geopolitical uncertainty continues to impact pharma sector investment decisions
Getinge says it is well positioned in prioritized product categories despite market uncertainty

Result Drivers
ACUTE CARE THERAPIES GROWTH - Sales increased in most product categories, with continued strong demand for ECLS therapy consumables
SURGICAL WORKFLOWS MOMENTUM - Co said Surgical Workflows continued to display good momentum
TARIFF REFUND AND OPERATIONAL GAINS - Adjusted EBITA margin was positively impacted by a SEK 336 mln tariff refund, favorable mix, price adaptations and productivity improvements

Company press release: ID:nWkr3fg71Y

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
 
SEK 3.59
 
Q2 Adjusted EBITA
 
SEK 1.48 bln
 
Q2 Adjusted Gross Profit
 
SEK 4.65 bln
 
Q2 Free Cash Flow
 
SEK 1.001 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Getinge publ AB is SEK222.00, about 5.2% above its July 16 closing price of SEK211.10
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)